You just read:

FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer

News provided by

Novartis Pharmaceuticals Corporation

May 24, 2019, 16:51 ET